BioNexus Gene Lab Corp Common stock (BGLC) Stock Analysis

BioNexus Gene Lab Corp Common stock (BGLC) is a publicly traded company in the BASIC MATERIALS sector. It trades at $2.30, carries a market capitalization of $5.41M. This page summarizes the public market data, fundamentals, and frequently asked questions for BGLC, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: BASIC MATERIALS - SPECIALTY CHEMICALS

Exchange: NASDAQ

Key Metrics

• Price: $2.30
• Market Cap: $5.41M
• EPS: $-1.48
• 52-Week High: $15.60
• 52-Week Low: $1.92

Market Sentiment

BioNexus Gene Lab Corp Common stock currently has a Bullish sentiment score of 0.20.

About BioNexus Gene Lab Corp Common stock

BioNexus Gene Lab Corp (BGLC) is a biotechnology firm based in Kuala Lumpur, Malaysia, dedicated to pioneering advancements in genetic research and innovative therapeutic solutions. Positioned at the forefront of the biotechnology sector, BGLC harnesses state-of-the-art gene editing and biomanufacturing methodologies to tackle critical healthcare challenges. The company boasts a promising product pipeline targeting improvements in human health and agricultural productivity, thereby capitalizi...

GNG Research Analysis

GNG Research scores BioNexus Gene Lab Corp Common stock (BGLC) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for BGLC.

Frequently Asked Questions

Does BGLC pay dividends?

BioNexus Gene Lab Corp Common stock (BGLC) does not currently pay a regular dividend.

What is BGLC's market cap?

BioNexus Gene Lab Corp Common stock (BGLC) has a market capitalization of $5.41M with a current stock price of $2.30.